Hepatic insulin resistance affects the efficacy of metformin in patients with newly diagnosed type 2 diabetes: A Sub-Analysis of the MARCH trial
Authors' conclusion
Patients with higher levels of hepatic IR obtained better curative effects from metformin in terms of glycemic control, insulin saving, insulin sensitivity enhancement, and IR improvement. Higher fasting blood glucose, fasting insulin, HOMA-β, IR, and lower Matsuda index were indicators of better hepatic IR improvement.
Study context
- Population
- Patients with newly diagnosed T2D allocated to 48-week metformin treatment in the MARCH trialmetformin arm
- Participants
- 291 patients
- Comparison
- Low vs medium vs high hepatic insulin resistance index (hepatic insulin resistance indexes (HIRI)) tertiles in metformin-treated patients
- Primary endpoint
- Influence of hepatic insulin resistance (IR) on the efficacy of metformin treatment
- Follow-up
- 48 weeks
Methodological detailssub-analysis, tertiles by baseline HIRI and by ΔHIRI
- Sub-analysis
- Tertiles by baseline HIRI and by ΔHIRI
Primary result
As reported in the abstract
Association of baseline HIRI with treatment response (multiple linear regression)
- Baseline HIRI positively associated with the rise in Matsuda index and the fall in FPG, fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR) and HIRI
Further findings
Predictors of decrease in HIRI · 48 weeks
- Baseline fasting insulin, HOMA-β, HOMA-IR and HIRI positively associated with the decrease in HIRI
- Baseline Matsuda index negatively associated with the decrease in HIRI
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Hepatic insulin resistance affects the efficacy of metformin in patients with newly diagnosed type 2 diabetes: A Sub-Analysis of the MARCH trial. Diabetes Res Clin Pract. Published 19 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →